PROTACs: the future of leukemia therapeutics
The fight to find effective, long-lasting treatments for cancer has led many researchers to
consider protein degrading entities. Recent developments in PROteolysis TArgeting …
consider protein degrading entities. Recent developments in PROteolysis TArgeting …
The Downregulation of Both Giant HERCs, HERC1 and HERC2, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with …
MS Ali, S Magnati, C Panuzzo, D Cilloni… - Journal of clinical …, 2022 - mdpi.com
Large HERC E3 ubiquitin ligase family members, HERC1 and HERC2, are staggeringly
complex proteins that can intervene in a wide range of biological processes, such as cell …
complex proteins that can intervene in a wide range of biological processes, such as cell …
mTORC2 is activated under hypoxia and could support chronic myeloid leukemia stem cells
C Panuzzo, L Pironi, A Maglione, S Rocco… - International Journal of …, 2023 - mdpi.com
Hypoxia is a critical condition that governs survival, self-renewal, quiescence, metabolic shift
and refractoriness to leukemic stem cell (LSC) therapy. The present study aims to investigate …
and refractoriness to leukemic stem cell (LSC) therapy. The present study aims to investigate …